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SHARED DRUG TARGETS IN DRUGBANK
Horacio Cañiza*, Diego Galeano*, and Alberto Paccanaro
Abstract— The current drug development pipelines are characterised by long processes with high attrition rates and elevated 
costs. More than 80% of new compounds fail in the later stages of testing due to severe side-effects caused by unknown 
biomolecular targets of the compounds. In this work, we present a measure that can predict shared targets for drugs in 
DrugBank through large scale analysis of the biomedical literature. We show that using MeSH ontology terms can accurately 
describe the drugs and that appropriate use of the MeSH ontological structure can determine pairwise drug similarity. Index 
Terms — MeSH terms, drug descriptors, drug targets, drugbank
1 INTRODUCTION
DESPITE breakthroughs in genomics [1], elucidating the molecular modes of action of pharmaceutical 
drugs has proven to be a difficult problem. Current drug 
discovery follows a pipeline characterised by a drawn-out 
process with low success rates and high costs [2].
The drug discovery process begins with the identifica- 
tion of a specific protein target whose behaviour the drug 
aims to change [3]. However, drugs tend to interact with 
proteins other than the intended target. These off-target 
effects disrupt the function of proteins that are usually 
unrelated to the condition the drug aims to treat. Most 
severe off-target effects are discovered during the final 
clinical trials in humans, an important cause of attrition in 
the pipeline [4]. Computational prediction of on/off tar- 
get effects of drugs can help stem the high attrition rates 
before clinical trials, reduce patient risk and drug devel- 
opment costs [5].
Starting in the 2017 XML release (version 5.0.5) Drug- 
Bank [6] incorporates MeSH (Medical Subject Headings) 
terms into its entries [7]. MeSH is a controlled vocabulary 
organised into 16 interconnected, hierarchically organised 
ontologies describing different areas of knowledge (e.g. 
Anatomy). MeSH was designed to index the biomedical 
literature in Medline/PubMed. The structure and content 
of these large-scale hand-curated ontologies have also 
been shown to be effective in quantifying pairwise dis- 
ease similarity, determining the distance between disease 
modules on the Interactome, and building disease- 
symptoms networks [8,9, 10, 11].
In this work, we present a MeSH based method to 
quantify pairwise drug similarities. We show that the con- 
tent of the MeSH ontologies can be used to accurately
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describe FDA approved drugs in DrugBank. We also 
show that the structure of the MeSH ontology, when used 
appropriately, outperforms the Tanimoto chemical simi- 
larity index, in terms of predicting share targets. Fur- 
thermore, we show that although the Tanimoto chemical 
similarity is good predictors of share targets for highly 
similar drugs (Tanimoto score > 60%) [12], in general, Tan- 
imoto scores are not good predictors of on/off targets for 
chemically dissimilar drugs [12].
2 Ma t e r i a l s  a n d  m e t h o d s
The approach we present here characterises FDA ap- 
proved drugs through sets of MeSH terms. We construct 
the set of annotations for a drug by combining the MeSH 
terms available in DrugBank and the set of MeSH terms 
annotating the publications referenced in the drug's 
DrugBank entry. The similarity between two drugs is then 
quantified by the semantic similarity of their annotations. 
An outline of our method is presented in Fig. 1.
Fig.1. Outline of the Mesh ontology based drug similarity. For each 
pair of FDA-approved drug in Drugbank, we obtained the MeSH 
terms associated to the drug entry and retrieved also the MeSH 
terms associated to the publications for each drug as listed in the 
database. The set of MeSH terms associated to each drug, e.g., Aspi- 
rin (blue terms) and Paracetamol (red terms) were annotated into the 
MeSH ontology. Several ontology-based similarity measures were 
computed between these terms and obtained a single number that
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indicates the similarity between the two drugs.
The Drugbank database [6] is a chemoinformatics re- 
source that combines information about known drug 
compounds, e.g. drug chemical structure, their Anatomi- 
cal Therapeutic and Chemical (ATC) category, their 
known biomolecular targets and references to the relevant 
publications. The current release contains 8,261 com- 
pounds and 4,338 non-redundant drug targets. In this 
work, we analyse the set of 1,416 FDA approved drugs 
with known targets and SMILES (Simplified Molecular- 
Input Line-Entry System) representation of the drug 
chemical structure.
A drug is annotated with the set of MeSH terms avail- 
able in DrugBank. Terms in each MeSH ontology are or- 
ganised in increasing specificity as a Directed Acyclic 
Graph (DAG) and a term can belong to multiple ontolo- 
gies. For example, Anatomy [A] -> Body Regions [A01] -> 
Extremities [A01.378] -> Upper Extremity [A.01.378.000] - 
> Hand [A.01.378.000.667] -> Wrist [A.01.378.000.667.715]. 
We enrich this set of MeSH available in DrugBank terms 
by mining the MeSH terms from the literature referenced 
in the drug's entry. The procedure for annotation of drug 
MeSH terms and ontology combination follows the pro- 
cedure presented in [10].
The similarity of a pair of drugs is given by the seman- 
tic similarity of the MeSH terms in the ontology. We 
evaluated a set of representative semantic similarity 
measures. The summary of the semantic similarity 
measures is presented in Table 1.
The individual MeSH ontologies are combined into a 
single ontology [10]. We have terms annotated in 15 
MeSH ontologies. The chosen ontologies are the ones 
that annotate most terms, namely Anatomy (A), Diseas- 
es (C) and Phenomena and Processes (G), and remove 
those that may introduce bias in the performance evalu- 
ation. Importantly, the Chemical and Drugs [D] ontology 
in MeSH contains biomolecular information [7]. For this 
reason, the entire Chemicals and Drugs ontology is re­
moved and all its terms ignored in the semantic similari- 
ty calculations. In addition, we combine the ontologies 
by introducing a root node linked to the root nodes of 
the chosen ontologies [10].
To evaluate our method, we define a binary classifica- 
tion problem in which the pairwise MeSH based similari- 
ty scores are used to predict share on/off targets for two 
drugs. The performance of the classification is given by 
the area under the ROC curve (AUC). The classification 
performance of the MeSH based similarity measures are 
compared to that of the Tanimoto chemical similarity [12]. 
For a pair of drugs, the Tanimoto similarity is determined 
by comparing the SMILES binary fingerprint of the drug 
compounds.
Formally the Tanimoto chemical similarity of two 
drugs D a  and D b is given by:
where Fa and Fb are the hash fingerprints for drugs D a  
and D b, respectively.
TABLE1
SUMMARY OF THE SEMANTIC SIMILARITY 
MEASURES
Method Definition
Resnik
[13]
Lin [14]
Jiang
[15]
simUI
[16]
simGIC
[17]
Jaccard
[18]
Num- 
ber of 
com-
mon
terms
LCA denotes the lowest common ancestor between a pair o f terms in the 
ontology and P(a) denotes the probability of a term in the ontology, given 
by the fraction of terms annotated by the term and the total number o f an- 
notations.
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3 Re s u l t s
We analyse 1,416 FDA approved drugs with known 
SMILES 2D chemical structure. We evaluate the perfor­
mance of the measures via binary classification problem 
where the pairwise drug similarities are used to predict 
whether two drugs share an on/off target. The perfor­
mance of the measures is evaluated by computing the 
area under the ROC curve (AUC). Fig. 2 shows the ROC 
curves for the representative set of semantic similarity 
measures evaluated (Resnik [13], Lin [14], Jiang and Con- 
rah [15], SIMui [16] and simGIC [17]), similarities meas- 
ure based on set intersection that do not consider the 
structure of the ontology (Overlap, Jaccard and Shared 
terms) and our baseline Tanimoto chemical similarity 
measure. The best performing method is SIMui, a seman- 
tic based measure.
To understand the performance of the prediction, the 
probability density function for Tanimoto chemical simi- 
larity and the MeSH based method SIMui is shown in 
Figure 3. The top figure shows the distribution of similari- 
ties for all the pairs, with the blue bars representing the 
Tanimoto similarity values and the orange bars the SIMui 
values. The mean similarity for the Tanimoto similarity 
values is 0.37 and for SIMui 0.16.
Fig. 2. Performance of the semantic-based similarity measures. 
Each ROC curve shows the performance of the corresponding se- 
mantic similarity method. The AUC for each method is shown in the 
legend. The baseline method is the Tanimoto chemical similarity (red 
line). SIMui is the semantic-based similarity that obtains the highest 
AUC in the prediction.
shared pairs. In both cases the difference in means is sig- 
nificant (P value 0.0 within machine precision). Compar- 
ing the difference in means between pairs with shared 
targets and not shared targets for SIMui is 0.1 and for 
Tanimoto 0.04. The difference is significant with a P value 
of 0.0 (within machine precission).
Fig.3. Distribution of similarity values. (Top) Probability density 
function of the pairwise similarity values for SIMui and Tanimoto 
similarities. (Bottom) Comparison of the distribution of pairwise 
similarity values between drug pairs with and without shared tar- 
gets.
One important question is to understand to what ex- 
tent the method's performance is dependent on the quali- 
ty of the annotations, on the ontological structure, or 
both. To assess the effects of MeSH's ontological struc- 
ture, we analysed the performance of similarity measures 
which disregard the ontology structure and are based on 
the overlap of the MeSH ontology terms annotating the 
drugs. For instance, in Figure 4 we show that Jaccard in- 
dex performs with an AUC of 0.68, only 1% below our 
best performing method. While the structure of the ontol- 
ogy provides valuable information, and improves the 
performance of our method, the MeSH terms themselves 
are accurate descriptors of FDA approved drugs.
Fig. 3 bottom compares, for both measures, the distri- 
bution of similarity scores for diseases with and without
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Fig.4. Performance of set intersection-based similarity measures. 
Each ROC curve shows the performance of the corresponding se- 
mantic similarity method. The AUC for each method is shown in the 
legend. The baseline method is the Tanimoto chemical similarity (red 
line). Jaccard index is as good predictor of shared targets as seman- 
tic-based similarity measures.
4 Di s c u s s i o n
In this paper, we introduced a method that uses MeSH 
ontology terms to accurately describe 1,416 FDA- 
approved drugs in DrugBank. We have shown that the 
semantic similarity measures can be used to predict 
whether two drugs share targets. Our method SIMui out- 
performs the Tanimoto chemical similarity by 10% AUC, 
as showed in Fig. 2.
Interestingly, biological evidence indicates that chemi- 
cal similarity is not always a good indicator of shared 
targets [18], i.e.: i) the chemical space of the binding site 
of the protein target may be wide, meaning that drugs 
with different chemical structures can bind to the same 
protein; ii) binding sites in proteins can be rather differ- 
ent; iii) high chemical similarity does not always imply 
shared protein targets [12]. To illustrate this point, we 
present in Table 2 a set of examples that have low Tan- 
imoto similarity and high SIMui that are known to share 
targets.
calculating distances between the sets of terms. The pair- 
wise drug similarity has shown to be a good predictor of 
shared targets between drugs and can be further incorpo- 
rated in advanced Machine Learning methods to enhance 
drug target prediction.
TABLE 2
DRUGS KNOWN TO SHARE TARGETS
Representative pair of FDA-approved drugs known to share targets. Tan- 
imoto chemical similarity does not suggest shared targets (< 40%) whereas 
SIMui drug similarity is above 80%.
Our analysis shows that the MeSH terms associated to 
publications referenced in DrugBank are good descriptors 
of FDA-approved drugs, and that the MeSH ontology 
structure provides valuable hierarchical information for
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